Suchergebnisse - "Vaz, Victor R"

PubPharm (11)

1

Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Ricciuti, B. | Lamberti, G. | Puchala, S. | +30

2

Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors

enthalten in: Cancer discovery | 2024

von Pecci, F. | Nakazawa, S. | Ricciuti, B. | +38

3

Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Alessi, J. | Wang, X. | Elkrief, A. | +32

4

Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy : tumor response dynamics as a marker for survival

enthalten in: European radiology | 2023

von Nishino, M. | Wang, X. | Ricciuti, B. | +8

5

Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Ricciuti, B. | Elkrief, A. | Alessi, J. | +30

CommentIn: Transl Lung Cancer Res. 2024 Mar 29;13(3):699-705. - PMID 38601449

6

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Alessi, J. | Elkrief, A. | Ricciuti, B. | +25

CommentIn: J Thorac Oncol. 2023 Jun;18(6):682-685. - PMID 37210177

7

Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival

enthalten in: European radiology | 2023

von Nishino, M. | Wang, X. | Ricciuti, B. | +8

8

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

enthalten in: JAMA oncology | 2022

von Ricciuti, B. | Wang, X. | Alessi, J. | +35

ErratumIn: JAMA Oncol. 2022 Nov 1;8(11):1702. - PMID 36394573

9

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Ricciuti, B. | Arbour, K. | Lin, J. | +30

CommentIn: J Thorac Oncol. 2022 Mar;17(3):351-352. - PMID 35216730

10

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations

enthalten in: Journal for immunotherapy of cancer | 2022

von Cortellini, A. | Ricciuti, B. | Vaz, V. | +32